AdAlta

Webinars

Updates

Home

Why Invest

Announcements

Lora

As AdAlta moves towards securing the partners and financing to progress AD-214 into Phase II clinical trials, we are now able to convene our Clinical Advisory Board (CAB) and appoint an additional translational science adviser. These are important milestones in the Company’s ongoing preparations for  Phase II clinical trials of AD-214, a first-in-class molecule that has shown promise to improve outcomes for the more than 500,000 IPF patients worldwide for whom the disease is terminal.

AD-214 clinical advisory board

Announcement summary